This disclosure relates to implantable, expandable gastric devices. In particular, this disclosure relates to improved structures of balloons and methods of producing the same.
Many conventional implantable gastric devices have a balloon filled with a biocompatible fluid. Such gastric devices are generally inserted into the stomach when the balloon is deflated and then inflated in vivo. The gastric devices are often left in the stomach for an extended period of time to treat severe obesity or other conditions. The gastric devices are eventually removed after completing the treatment or for other reasons by deflating the balloon, grasping the gastric device with an extraction tool, and extracting the gastric device via the esophagus and mouth. Conventional gastric devices are deflated by attempting to puncture the balloon and aspirate the biocompatible fluid through a needle.
One challenge of conventional devices is that the balloon are generally fairly large in a deflated state because of the limited elasticity and expansion of the materials that can withstand the harsh environment within the stomach rupture. Many existing balloons for intragastric devices are made from polydiphenylsiloxane (PDPS), which resists degradation by acids, fungal growth and other microbial growth, but it has limited expansion. As such, the cuffs of such a balloon must have a fairly large diameter so that the balloon can be removed from a mandrel during the manufacturing process.
Another challenge of conventional intragastric devices is the life span of the balloon. For example, fungi or other microbes can grow into the material of the balloon and effectively decrease the wall thickness. This can weaken the balloon wall to the point that it ruptures under the pressure of the fluid in the balloon.
Several embodiments of the present technology will become more apparent with reference to the following description taken in conjunction with the accompanying drawings wherein like reference numerals denote like elements and in which:
Specific details of several embodiments of the present technology are described below with reference to an intragastric device with compound balloon. Although many of the embodiments are described below with respect to a dual balloon intragastric device, other types of devices with only one balloon or more than two balloons may be within the scope of the technology. Moreover, several other embodiments of the technology can have different configurations, components, or procedures than those described in this section. A person of ordinary skill in the art, therefore, will accordingly understand that the technology may have other embodiments with additional elements, or the technology may have other embodiments without several of the features shown and described below with reference to
Several embodiments of the technology are directed to a balloon of an intragastric device comprising, in combination, a substrate or core of a first material that has having an inner surface and an outer surface, and a coating of a second material on at least one of the inner or outer surfaces. The substrate, for example, can be more elastic and/or have more expansion than the coating, and the coating can be more resistant to fungal or other microbial growth than the substrate.
Additional embodiments of the technology are directed to a method comprising, in combination, forming a core or substrate of a first material into a balloon and covering at least one of an inner surface and/or outer surface of the substrate with a second material. The second material can be a coating that is sprayed, painted or applied by dipping the substrate into the second material, to form a smoother surface finish, as compared to a surface finish of a molded core, having a roughness from about 0.1 to 0.7 micron. This further inhibits or otherwise impedes the formation of biofilm (e.g., candida) on the coated surface of the balloon. Also disclosed are products by processed disclosed herein.
The first material may be of a more dimensionally stable or consistant than the second material and/or have a greater elasticity than the second material. In one embodiment, the first material comprises polydimethylsiloxane (PDMS). The second material may have a higher resistance to acid, be more resistant to fungal or other microbial activity, and be less permeable than the first material. In one embodiment, the second material comprises PDPS.
In the specific embodiment shown in
The balloon 30 may have many different geometries and shapes according to the specific anatomy in which the balloon 30 is implanted. As shown in
According to several embodiments of the technology, the intragastric device 10 may be configured for use as an implantable device within a gastric cavity. In many applications, the intragastric device 10 is implanted for several months in the stomach or other gastric cavity having high concentrations of acids and microbes that can deteriorate the balloon 30. The durability and longevity of the intragastric device 10 is accordingly defined, at least in part, by the ability of the balloon 30 to resist the harsh environment within the stomach. As such, the materials and manufacturing methods of the materials are key contributors as to balloon integrity and longevity.
According to embodiments, the balloon 30 may comprise a combination of two different silicone-containing materials. Two examples of such materials are PDMS and PDPS. PDMS may be represented as [SiO(CH3)2]n or graphically as follows:
PDPS may be represented as [SiO(C6H5)2]n or graphically as follows:
According to several embodiments of the technology, at least one of PDMS and PDPS may form the substrate or core of at least a portion of the balloon 30. Other materials, structures, or compounds may be mixed or cross-linked with the based material.
According to several embodiments of the technology, a plasma etching or coating may be provided to at least a portion of the balloon 30. Plasma etching may involve a high-speed stream of glow discharge (plasma) of an appropriate gas mixture being shot (in pulses) at a sample. The plasma source can be either charged (ions) or neutral (atoms and radicals). During the process, the plasma will generate volatile etch products at room temperature from the chemical reactions between the elements of the material etched and the reactive species generated by the plasma. The atoms of the shot element embed themselves at or just below the surface of the target, thus modifying the physical properties of the balloon 30. Etching may facilitate better adherence between layers of the balloon 30.
According to several embodiments of the technology, various coatings (e.g., hydrophilic) may be applied to at least a portion of substrate or core of the balloon 30. For example, a hydrophilic coating may be provided where two surfaces of the balloon 30 resist flow of fluid there through.
The respective chemical structures of PDMS and PDPS have relatively disparate characteristics, which may be summarized as follows:
In various applications and based on different aspects, each of PDMS and PDPS may be seen as providing certain advantages and disadvantages.
According to several embodiments of the technology, the dimensional stability or consistency and elasticity of PDMS materials and PDMS blends enable the balloon 30 to be formed using molding and extrusion processes instead of a dipping process. In particular, molding processes include molding the PDMS material over a mandrel, and the higher elasticities of PDMS materials compared to PDPS materials reduce the stresses involved in removing the mandrel. For example, the balloon 30 may be formed using a mandrel that has a larger diameter at a central portion than at one or both ends (corresponding to cuffs 40). For example, the diameter at the middle of a mandrel may be up to 600% larger than at the end of the mandrel. The balloon 30 must sufficiently elastic to remove the mandrel through the cuff 40 without damaging the cuff 40.
According to several embodiments of the technology, the expansion ratio of the balloon 30 from an uninflated state (i.e., before and during implant) to an inflated state (i.e, after implant) may be significant. For example, the balloon 30 may have an outer diameter of about 1.9″ in an uninflated state and about 4″ in an inflated state (over 200% expansion). By further example, the balloon 30 may have a volume of about 80 cc in an uninflated state and about 450 cc in an inflated state (over 500% expansion). These factors are well-served by PDMS materials and PDMS blends. As such, PDMS and PDMS blends are well suited for the substrate or core of the balloon 30.
In accordance with several embodiments of the invention, the higher acid resistance and less permeability of PDPS materials and PDPS blends, compared to PDMS based materials, better limit the ingress or egress of materials across the walls of the balloon 30 and support longevity of the balloon 30. Generally, PDPS, as compared to PDMS, is less able to provide consistent wall thicknesses and is less capable of generating molding friendly features, but more capable of resisting acids and growth of fungi or bacteria.
In several specific embodiments of the technology, the balloon 30 has a multiple-material composition in which a plurality of disparate materials and material blends may be provide in layers forming walls of the balloon 30. For example, a wall of the balloon 30 may have a substrate or core with at least one coating on an inner or outer surface thereof.
In selected embodiments, the substrate or core 50 can comprise PDMS or another material that is moldable and has a higher elasticity than PDPS. The inner and/or outer coatings 60a-b can comprises PDPS or another material that is less permeable and more acid resistant than PDMS. According to several embodiments, the balloon 30 having a layered, multiple-material composition may benefit from the advantaged of each material while mitigating or minimizing the detriments of each.
The present technology is also directed to methods of making the balloon 30 is disclosed. In one embodiment, the substrate or core 50 may be molded of the first material, such as a liquid silicone rubber (LSR) grade material (e.g., such as PDMS). Those skilled in the art will recognize various molding and extrusion processes that may facilitate formation of core 50. The molding process can include injecting PDMS or a PDMS blend into a mold such that the molded material surrounds a mandrel or other form. After curing, the core 50 is removed from the mold, mandrel, or other device, and then the second material may be coated onto the inner and/or outer surface of the core 50. For example, the core 50 may be dipped in the second material to form at least one of the outer coating 60a and/or the inner coating 60b. Other embodiments of the method, the core 50 may be coated using other techniques, such as spraying, painting, coating, washing, etc. The second material can be PDPS or another suitable low-permeable, acid and fungal resistant material.
The core 50 may compose a substantial portion of the total sum of the balloon 30 or at least the walls thereof. For example, the thickness of core 50 may be about 0.001 inch to about 1.0 inch. By further example, the thickness of core 50 may be about 0.024 inch to about 0.030 inch. The core 50 can have other thicknesses based on the needs and applications of the desired product.
The outer coating 60a or the inner coating 60b may be a thin relative to the thickness of core 50. For example, the outer coating 60a or the inner coating 60b may have a thickness of about 1% to about 99% of the thickness of core 50. By further example, the outer coating 60a or the inner coating 60b may have a thickness of about 10% to about 20% of the thickness of core 50. The inner and outer coating 60a-b can have other thicknesses based on the needs and applications of the desired product. It should be noted that outer coating 60a or inner coating 60b comprising PDPS materials increase the stiffness of the balloon 30 and reduce elongation properties thereof.
In still additional embodiments of the technology, the core 50 and/or the coating 60 can include anti-microbial or other additives to impart additional therapeutic, durability, or other properties to the balloon 30. For example, such additives can be distributed homogeneously in the coating 60, or the additives can be a constituent of another coating applied directly to the core 50 or to the coating 60. When such an additional coating is applied directly to the core 50, the coating 60 can be applied onto the other coating. In several specific examples, the additives can comprise salt or silver-based anti-microbial materials that inhibit the growth of microbes on and/or into the core 50.
The multi-layered construction of first and second materials of several embodiments of the balloon may have a substantially consistent surface and retain elastic material properties, increased acid resistance, and lower permeability. For example, the first material of the core 50 can provide good elasticity enable molding processes that provide a controlled wall thickness, and the second material of the coating 60 can provide good resistance to acid, fungus, bacteria and other microbes. The second material of the coating 60 can also have a low permeability.
Although the method and agent have been described in terms of what are presently considered to be the most practical and preferred embodiments, it is to be understood that the disclosure need not be limited to the disclosed embodiments. It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar structures. The present disclosure includes any and all embodiments of the following claims.
It should also be understood that a variety of changes may be made without departing from the essence of the invention. Such changes are also implicitly included in the description. They still fall within the scope of this invention. It should be understood that this disclosure is intended to yield a patent covering numerous aspects of the invention both independently and as an overall system and in both method and apparatus modes.
Further, each of the various elements of the invention and claims may also be achieved in a variety of manners. This disclosure should be understood to encompass each such variation, be it a variation of an embodiment of any apparatus embodiment, a method or process embodiment, or even merely a variation of any element of these.
Particularly, it should be understood that as the disclosure relates to elements of the invention, the words for each element may be expressed by equivalent apparatus terms or method terms—even if only the function or result is the same.
Such equivalent, broader, or even more generic terms should be considered to be encompassed in the description of each element or action. Such terms can be substituted where desired to make explicit the implicitly broad coverage to which this invention is entitled.
It should be understood that all actions may be expressed as a means for taking that action or as an element which causes that action.
Similarly, each physical element disclosed should be understood to encompass a disclosure of the action which that physical element facilitates.
Any patents, publications, or other references mentioned in this application for patent are hereby incorporated by reference. In addition, as to each term used it should be understood that unless its utilization in this application is inconsistent with such interpretation, common dictionary definitions should be understood as incorporated for each term and all definitions, alternative terms, and synonyms such as contained in at least one of a standard technical dictionary recognized by artisans and the Random House Webster's Unabridged Dictionary, latest edition are hereby incorporated by reference.
Finally, all referenced listed in the Information Disclosure Statement or other information statement filed with the application are hereby appended and hereby incorporated by reference; however, as to each of the above, to the extent that such information or statements incorporated by reference might be considered inconsistent with the patenting of this/these invention(s), such statements are expressly not to be considered as made by the applicant(s).
In this regard it should be understood that for practical reasons and so as to avoid adding potentially hundreds of claims, the applicant has presented claims with initial dependencies only.
Support should be understood to exist to the degree required under new matter laws—including but not limited to United States Patent Law 35 USC 132 or other such laws—to permit the addition of any of the various dependencies or other elements presented under one independent claim or concept as dependencies or elements under any other independent claim or concept.
To the extent that insubstantial substitutes are made, to the extent that the applicant did not in fact draft any claim so as to literally encompass any particular embodiment, and to the extent otherwise applicable, the applicant should not be understood to have in any way intended to or actually relinquished such coverage as the applicant simply may not have been able to anticipate all eventualities; one skilled in the art, should not be reasonably expected to have drafted a claim that would have literally encompassed such alternative embodiments.
Further, the use of the transitional phrase “comprising” is used to maintain the “open-end” claims herein, according to traditional claim interpretation. Thus, unless the context requires otherwise, it should be understood that the term “compromise” or variations such as “comprises” or “comprising”, are intended to imply the inclusion of a stated element or step or group of elements or steps but not the exclusion of any other element or step or group of elements or steps.
Such terms should be interpreted in their most expansive forms so as to afford the applicant the broadest coverage legally permissible.
The present application is a divisional of U.S. application Ser. No. 13/577,618, filed Aug. 28, 2012, which is a national stage entry of PCT Application No. PCT/US2011/024082, filed Feb. 8, 2011, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61/302,465, filed Feb. 8, 2010, the disclosures of which are incorporated herein by reference in their entireties. This application incorporates by reference: U.S. Pat. Pub. No. 2007/0100367, published May 3, 2007; U.S. Pat. Pub. No. 2007/0100368, published May 3, 2007; U.S. Pat. Pub. No. 2007/0100369, published May 3, 2007; U.S. Pat. Pub. No. 2007/0149994, published Jun. 28, 2007; U.S. Pat. Pub. No. 2008/0243071, published Oct. 2, 2008; U.S. Pat. Pub. No. 2008/0319471, published Dec. 25, 2008; U.S. Pat. Pub. No. 2005/0159769, published Jul. 21, 2005; U.S. Pat. Pub. No. 2009/0048624, published Feb. 19, 2009; WIPO Pub. No. WO 2007/053556, published Oct. 5, 2007; WIPO Pub. No. WO 2007/053707, published Oct. 5, 2007; WIPO Pub. No. WO 2007/053706, published Oct. 5, 2007; and WIPO Pub. No. WO 2007/075810, published May 7, 2007; each as if fully set forth herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
1666690 | Drevitson | Apr 1928 | A |
1690995 | Pratt | Nov 1928 | A |
2493326 | Trinder | Jan 1950 | A |
2579301 | Buntin | Dec 1951 | A |
3131867 | Miller et al. | May 1964 | A |
4133315 | Berman et al. | Jan 1979 | A |
4198983 | Becker et al. | Apr 1980 | A |
4246893 | Berson | Jan 1981 | A |
4356824 | Vazquez | Nov 1982 | A |
4368739 | Nelson, Jr. | Jan 1983 | A |
4416267 | Garren et al. | Nov 1983 | A |
4465072 | Taheri | Aug 1984 | A |
4465818 | Shirahata et al. | Aug 1984 | A |
4485805 | Foster, Jr. | Dec 1984 | A |
4543089 | Moss | Sep 1985 | A |
4598699 | Garren et al. | Jul 1986 | A |
4694827 | Weiner et al. | Sep 1987 | A |
4723547 | Kullas et al. | Feb 1988 | A |
4899747 | Garren et al. | Feb 1990 | A |
4940458 | Cohn | Jul 1990 | A |
5073347 | Garren et al. | Dec 1991 | A |
5084061 | Gau et al. | Jan 1992 | A |
5123840 | Nates | Jun 1992 | A |
5234454 | Bangs | Aug 1993 | A |
5259399 | Brown | Nov 1993 | A |
5263934 | Haak | Nov 1993 | A |
5273536 | Savas | Dec 1993 | A |
5318530 | Nelson, Jr. | Jun 1994 | A |
5334187 | Fischell et al. | Aug 1994 | A |
5431173 | Chin et al. | Jul 1995 | A |
5496271 | Burton et al. | Mar 1996 | A |
5516812 | Chu et al. | May 1996 | A |
5575772 | Lennox | Nov 1996 | A |
5639810 | Smith, III et al. | Jun 1997 | A |
5643209 | Fugoso et al. | Jul 1997 | A |
5730722 | Wilk | Mar 1998 | A |
5779728 | Lunsford et al. | Jul 1998 | A |
5857991 | Grothoff et al. | Jan 1999 | A |
5876376 | Schwab et al. | Mar 1999 | A |
5904701 | Daneshvar | May 1999 | A |
5938669 | Klaiber et al. | Aug 1999 | A |
5976073 | Ouchi | Nov 1999 | A |
5993473 | Chan et al. | Nov 1999 | A |
5997503 | Willis et al. | Dec 1999 | A |
6050274 | Gelardi et al. | Apr 2000 | A |
6149621 | Makihara | Nov 2000 | A |
6179878 | Duerig et al. | Jan 2001 | B1 |
6254355 | Gharib | Jul 2001 | B1 |
6276567 | Diaz et al. | Aug 2001 | B1 |
6280411 | Lennox | Aug 2001 | B1 |
6423058 | Edwards et al. | Jul 2002 | B1 |
6427089 | Knowlton | Jul 2002 | B1 |
6454785 | De Hoyos Garza | Sep 2002 | B2 |
6524234 | Ouchi | Feb 2003 | B2 |
6535764 | Imran et al. | Mar 2003 | B2 |
6540789 | Silverman et al. | Apr 2003 | B1 |
6547788 | Maguire et al. | Apr 2003 | B1 |
6579301 | Bales et al. | Jun 2003 | B1 |
6592552 | Schmidt | Jul 2003 | B1 |
6613018 | Bagga et al. | Sep 2003 | B2 |
6613037 | Khosravi et al. | Sep 2003 | B2 |
6689051 | Nakada | Feb 2004 | B2 |
6706010 | Miki et al. | Mar 2004 | B1 |
6746460 | Gannoe et al. | Jun 2004 | B2 |
6826428 | Chen et al. | Nov 2004 | B1 |
6850128 | Park | Feb 2005 | B2 |
6866657 | Shchervinsky | Mar 2005 | B2 |
6869431 | Maguire et al. | Mar 2005 | B2 |
6890300 | Lloyd et al. | May 2005 | B2 |
6890346 | Ganz et al. | May 2005 | B2 |
6902535 | Eberhart et al. | Jun 2005 | B2 |
6923754 | Lubock | Aug 2005 | B2 |
6931286 | Sigg et al. | Aug 2005 | B2 |
6939299 | Petersen et al. | Sep 2005 | B1 |
6942680 | Grayzel et al. | Sep 2005 | B2 |
6958052 | Charlton | Oct 2005 | B1 |
6981980 | Sampson et al. | Jan 2006 | B2 |
7001419 | DiCaprio et al. | Feb 2006 | B2 |
7016735 | Imran et al. | Mar 2006 | B2 |
7020531 | Colliou et al. | Mar 2006 | B1 |
7033373 | de la Torre et al. | Apr 2006 | B2 |
7056305 | Garza Alvarez | Jun 2006 | B2 |
7076305 | Imran et al. | Jul 2006 | B2 |
7081125 | Edwards et al. | Jul 2006 | B2 |
7131945 | Fink et al. | Nov 2006 | B2 |
7483746 | Lee et al. | Jan 2009 | B2 |
7625355 | Yu | Dec 2009 | B2 |
7749254 | Sobelman et al. | Jul 2010 | B2 |
7828749 | Douglas et al. | Nov 2010 | B2 |
7829572 | Didiuk et al. | Nov 2010 | B2 |
7931693 | Binmoeller | Apr 2011 | B2 |
8083757 | Gannoe et al. | Dec 2011 | B2 |
8142469 | Sosnowski et al. | Mar 2012 | B2 |
8226602 | Quijana et al. | Jul 2012 | B2 |
8556925 | Makower et al. | Oct 2013 | B2 |
8683881 | Bouasaysy et al. | Apr 2014 | B2 |
8840952 | Ashby et al. | Sep 2014 | B2 |
8845672 | Alverdy | Sep 2014 | B2 |
8894568 | Kwok et al. | Nov 2014 | B2 |
9050174 | Pecor et al. | Jun 2015 | B2 |
20010022988 | Schwarz et al. | Sep 2001 | A1 |
20010037127 | De Hoyos Garza | Nov 2001 | A1 |
20020055757 | Torre et al. | May 2002 | A1 |
20020107515 | Edwards et al. | Aug 2002 | A1 |
20020161388 | Samuels et al. | Oct 2002 | A1 |
20020173804 | Rousseau | Nov 2002 | A1 |
20030105800 | Cullen | Jun 2003 | A1 |
20030114878 | Diederich et al. | Jun 2003 | A1 |
20030171768 | McGhan | Sep 2003 | A1 |
20030187390 | Bates et al. | Oct 2003 | A1 |
20040044354 | Gannoe et al. | Mar 2004 | A1 |
20040059289 | Garza Alvarez | Mar 2004 | A1 |
20040059290 | Palasis | Mar 2004 | A1 |
20040073162 | Bleam et al. | Apr 2004 | A1 |
20040087902 | Richter | May 2004 | A1 |
20040093058 | Cottone et al. | May 2004 | A1 |
20040106899 | McMichael et al. | Jun 2004 | A1 |
20040116897 | Aboul- Hosn | Jun 2004 | A1 |
20040127915 | Fleenor et al. | Jul 2004 | A1 |
20040220665 | Hossainy et al. | Nov 2004 | A1 |
20040236280 | Rice et al. | Nov 2004 | A1 |
20040236361 | Sakurai | Nov 2004 | A1 |
20040254600 | Zarbatany et al. | Dec 2004 | A1 |
20050027283 | Richard et al. | Feb 2005 | A1 |
20050027313 | Shaker | Feb 2005 | A1 |
20050038415 | Rohr et al. | Feb 2005 | A1 |
20050055039 | Burnett et al. | Mar 2005 | A1 |
20050059990 | Ayala et al. | Mar 2005 | A1 |
20050075624 | Miesel | Apr 2005 | A1 |
20050085792 | Gershowitz | Apr 2005 | A1 |
20050119674 | Gingras | Jun 2005 | A1 |
20050131442 | Yachia et al. | Jun 2005 | A1 |
20050143784 | Imran | Jun 2005 | A1 |
20050159769 | Alverdy | Jul 2005 | A1 |
20050177103 | Hunter et al. | Aug 2005 | A1 |
20050192615 | Torre et al. | Sep 2005 | A1 |
20050228504 | Demarais | Oct 2005 | A1 |
20050267595 | Chen et al. | Dec 2005 | A1 |
20050267596 | Chen et al. | Dec 2005 | A1 |
20050273060 | Levy et al. | Dec 2005 | A1 |
20060058829 | Sampson et al. | Mar 2006 | A1 |
20060142700 | Sobelman et al. | Jun 2006 | A1 |
20060178691 | Binmoeller | Aug 2006 | A1 |
20060184112 | Horn et al. | Aug 2006 | A1 |
20060259020 | Sharratt | Nov 2006 | A1 |
20070016262 | Gross et al. | Jan 2007 | A1 |
20070078476 | Hull et al. | Apr 2007 | A1 |
20070083224 | Hively | Apr 2007 | A1 |
20070100367 | Quijano et al. | May 2007 | A1 |
20070100368 | Quijano et al. | May 2007 | A1 |
20070100369 | Cragg et al. | May 2007 | A1 |
20070118168 | Lointier et al. | May 2007 | A1 |
20070135829 | Paganon | Jun 2007 | A1 |
20070142770 | Rioux et al. | Jun 2007 | A1 |
20070149994 | Sosnowski et al. | Jun 2007 | A1 |
20070173881 | Birk et al. | Jul 2007 | A1 |
20070233161 | Weller et al. | Oct 2007 | A1 |
20070250020 | Kim et al. | Oct 2007 | A1 |
20070265369 | Muratoglu et al. | Nov 2007 | A1 |
20070265598 | Karasik | Nov 2007 | A1 |
20070288033 | Murature et al. | Dec 2007 | A1 |
20080058887 | Griffin et al. | Mar 2008 | A1 |
20080082056 | Mauch et al. | Apr 2008 | A1 |
20080085887 | Didiuk et al. | Apr 2008 | A1 |
20080097513 | Kaji et al. | Apr 2008 | A1 |
20080119729 | Copa et al. | May 2008 | A1 |
20080172079 | Birk | Jul 2008 | A1 |
20080190363 | Chen et al. | Aug 2008 | A1 |
20080208135 | Annunziata | Aug 2008 | A1 |
20080208241 | Weiner et al. | Aug 2008 | A1 |
20080233167 | Li | Sep 2008 | A1 |
20080243071 | Quijano et al. | Oct 2008 | A1 |
20080243166 | Paganon et al. | Oct 2008 | A1 |
20080255601 | Birk | Oct 2008 | A1 |
20080312679 | Hardert et al. | Dec 2008 | A1 |
20080319471 | Sosnowski et al. | Dec 2008 | A1 |
20090048624 | Alverdy | Feb 2009 | A1 |
20090259236 | Burnett et al. | Oct 2009 | A2 |
20090275973 | Chen et al. | Nov 2009 | A1 |
20090287231 | Brooks et al. | Nov 2009 | A1 |
20100023047 | Simpson | Jan 2010 | A1 |
20100049224 | Vargas | Feb 2010 | A1 |
20100057197 | Weber | Mar 2010 | A1 |
20100063530 | Valencon et al. | Mar 2010 | A1 |
20100130998 | Alverdy | May 2010 | A1 |
20100174307 | Birk et al. | Jul 2010 | A1 |
20100191270 | Garza et al. | Jul 2010 | A1 |
20100234853 | Pecor et al. | Sep 2010 | A1 |
20100243135 | Pepper et al. | Sep 2010 | A1 |
20100251837 | Bouasaysy et al. | Oct 2010 | A1 |
20110172767 | Rathi et al. | Jul 2011 | A1 |
20110178544 | Sosnowski et al. | Jul 2011 | A1 |
20110276076 | Paganon | Nov 2011 | A1 |
20110295300 | Verd et al. | Dec 2011 | A1 |
20120191126 | Pecor et al. | Jul 2012 | A1 |
20120271336 | Hamman et al. | Oct 2012 | A1 |
20120271338 | Bouasaysy et al. | Oct 2012 | A1 |
20120289992 | Quijano et al. | Nov 2012 | A1 |
20130035710 | Bouasaysy et al. | Feb 2013 | A1 |
20130053880 | Bouasaysy et al. | Feb 2013 | A1 |
20130060274 | Bouasaysy | Mar 2013 | A1 |
20130102876 | Limon et al. | Apr 2013 | A1 |
20130261654 | Bouasaysy et al. | Oct 2013 | A1 |
20130296914 | Quijano et al. | Nov 2013 | A1 |
20140031850 | Bouasaysy et al. | Jan 2014 | A1 |
20140257358 | Alverdy | Sep 2014 | A1 |
20140371775 | Ashby et al. | Dec 2014 | A1 |
20150216529 | Kwok et al. | Aug 2015 | A1 |
20150238342 | Sosnowski et al. | Aug 2015 | A1 |
20150265811 | Pecor | Sep 2015 | A1 |
20160008156 | Pecor et al. | Jan 2016 | A1 |
Number | Date | Country |
---|---|---|
2638988 | May 2007 | CA |
8708978 | Nov 1987 | DE |
0103481 | Mar 1984 | EP |
0457456 | Nov 1991 | EP |
0485903 | May 1992 | EP |
1781183 | May 2007 | EP |
2862525 | May 2005 | FR |
2892297 | Apr 2007 | FR |
2090747 | Jul 1982 | GB |
2139902 | Nov 1984 | GB |
S57168674 | Oct 1982 | JP |
S6415063 | Jan 1989 | JP |
01091872 | Apr 1989 | JP |
H08322943 | Dec 1996 | JP |
2001128985 | May 2001 | JP |
2006333888 | Dec 2006 | JP |
2015154964 | Aug 2015 | JP |
2016127954 | Jul 2016 | JP |
8805671 | Aug 1988 | WO |
WO-9000369 | Jan 1990 | WO |
WO-9925418 | May 1999 | WO |
WO-0141700 | Jun 2001 | WO |
WO-0166166 | Sep 2001 | WO |
WO-0240081 | May 2002 | WO |
2005082296 | Sep 2005 | WO |
2005107641 | Nov 2005 | WO |
2005120363 | Dec 2005 | WO |
WO-2006035446 | Apr 2006 | WO |
WO-2006056944 | Jun 2006 | WO |
WO-2006128978 | Dec 2006 | WO |
WO-2007027812 | Mar 2007 | WO |
WO-2007053556 | May 2007 | WO |
WO-2007053706 | May 2007 | WO |
WO-2007053707 | May 2007 | WO |
WO-2007075810 | Jul 2007 | WO |
WO-2008042819 | Apr 2008 | WO |
WO-2008121831 | Oct 2008 | WO |
WO-2009055386 | Apr 2009 | WO |
WO-2009112786 | Sep 2009 | WO |
WO-2010048021 | Apr 2010 | WO |
WO-2010115161 | Oct 2010 | WO |
WO-2011011629 | Jan 2011 | WO |
WO-2011011741 | Jan 2011 | WO |
WO-2011011743 | Jan 2011 | WO |
WO-2011024077 | Mar 2011 | WO |
WO-2011038270 | Mar 2011 | WO |
WO-2011097637 | Aug 2011 | WO |
WO-2011127205 | Oct 2011 | WO |
WO-2012048226 | Apr 2012 | WO |
Entry |
---|
Canadian 2nd Office Action Application No. CA 2680124, Applicant: Reshape Medical, Inc., mailed Jul. 9, 2015, 3 pages. |
European Examination Report; Application No. EP06827313.5, Applicant: Reshape Medical Inc., mailed Jul. 13, 2015, 4 pages. |
European Examination Report; Application No. EP06847847.8, Applicant: Reshape Medical Inc., mailed Jul. 13, 2015, 4 pages. |
Cronin, Carmel G. et al., “Normal small bowel wall characteristics on MR enterography,” European Journal of Radiology 74(2):207-211, Aug. 2010. |
Gray, Henry, Anatomy of the Human Body. Philadelphia: Lea & Febiger, 1918. Section XI Splanchnology, 2g. The Small Intestine. Bartleby.com, 2000. Web. URL: www.bartleby.com/107/248.html. Accessed: Oct. 26, 2015. 12 pages. |
Partial Supplementary European Search Report for European Application No. 11740535.7, Applicant: ReShape Medical, Inc., mailed Oct. 20, 2015, 7 pages. |
Final Office Action for Japanese Application No. 2014-52972, Applicant: ReShape Medical, Inc., mailed on Oct. 9, 2015, 8 pages. |
“Living with the BIB: BioEnterics Intragastric Balloon Program: Patient Information”; INAMED Health: Bioenterics Corporation, ECO-SBA-10434; dated Apr. 20, 2004 and May 14, 2005, located online at: www.sydneyobesity.com.au/pdf/M946-01.pdf; 10 pages. |
Canadian 2nd Office Action Application No. CA 2484838, Applicant: ReShape Medical, Inc., mailed Sep. 24, 2010, 3 pages. |
Canadian Office Action: Application No. CA 2680124, Applicant: ReShape Medical Corporation, mailed Nov. 4, 2014, 3 pages. |
Canadian Office Action; Application No. CA 2484838, Applicant: ReShape Medical, Inc., mailed Nov. 13, 2009, 3 pages. |
Canadian Office Action; Application No. CA 2638163, Applicant: ReShape Medical Corporation, mailed Jul. 17, 2013, 2 pages. |
Canadian Office Action; Application No. CA 2638163, Applicant: ReShape Medical Corporation, mailed Mar. 10, 2015, 4 pages. |
Canadian Office Action; Application No. CA 2638988, Applicant ReShape Medical Corporation, mailed Dec. 22, 2014 3 pages. |
Canadian Office Action; Application No. CA 2638988, Applicant ReShape Medical Corporation, mailed Mar. 6, 2014, 4 pages. |
Canadian Office Action; Application No. CA 2638988, Applicant: ReShape Medical Corporation, mailed May 28, 2013, 3 pages. |
Canadian Office Action; Application No. CA 2638989, Applicant: ReShape Medical Corporation, mailed May 22, 2013 3 pages. |
Canadian Office Action; Application No. CA 2640554, Applicant: ReShape Medical Corporation, mailed May 27, 2013, 2 pages. |
Canadian Office Action; Application No. CA 2691530, mailed Dec. 18, 2014, 4 pages. |
Canadian Office Action; Application No. CA 2780085, Applicant: ReShape Medical, Inc., mailed Jul. 23, 2012, 2 pages. |
European Examination Report; Application No. 03726447.0, Applicant: Applied Medical Resources Corporation: Oct. 26, 2007, 4 pages. |
European Examination Report; Application No. EP 10802918.2, Applicant: ReShape Medical, Inc., mailed Dec. 17, 2014, 5 pages. |
European Examination Report; Application No. EP108029943, Applicant: ReShape Medical, Inc., mailed Dec. 18, 2014, 4 pages. |
European Examination Reported; Application No. 08771842.5, May 7, 2015, 5 pages. |
European Search Report—Supplementary; EP 03726447.0, Applicant: Applied Medical Resources Corporation: Mar. 1, 2006, 3 pages. |
European Supplementary Search Report; Application No. 08771842.5, Apr. 24, 2015, 3 pages. |
European Supplementary Search Report; EP Application No. 10802918.2, Applicant: ReShape Medical, Inc., mailed Jun. 5, 2013, 6 pages. |
European Supplementary Search Report; EP Application No. 10802994.3, Applicant: ReShape Medical, Inc., mailed Jun. 28, 2013, 8 pages. |
Extended European Search Report; Application No. 08732989.2, Applicant: ReShape Medical, Inc., mailed Oct. 16, 2014, 7 pages. |
Extended European Search Report; Application No. 11748141.6, Applicant: ReShape Medical Corporation, mailed Feb. 25, 2014, 6 pages. |
Extended European Search Report; Application No. EP11740536.5, Applicant: ReShape Medical, Inc., mailed Jul. 3, 2014, 8 pages. |
Extended European Search Report; Application No. EP11748141.6, Applicant: ReShape Medical, Inc., mailed Feb. 25, 2014, 6 pages. |
Extended European Search Report; Application No. EP11766679.2, Applicant: ReShape Medical, Inc., mailed Dec. 12, 2013, 6 pages. |
Extended European Search Report; Application No. EP11831683.5, Applicant: ReShape Medical, Inc., mailed Jul. 3, 2014, 8 pages. |
Extended European Search Report; Application No. EP6827098.3, Applicant: ReShape Medical, Corporation, mailed on Aug. 25, 2014, 3 pages. |
Extended European Search Report; Application No. EP6827313.5, Applicant: ReShape Medical Corporation, mailed Jul. 30, 2014, 5 pages. |
Extended European Search Report; Application No. EP6827314.3, Applicant: ReShape Medical Corporation, mailed Aug. 1, 2014, 3 pages. |
Extended European Search Report; application No. EP6847847.8, Applicant ReShape Medical Corporation, mailed Aug. 14, 2014, 5 pages. |
International Search Report; International Application No. PCT/US11/55373, Applicant: ReShape Medical, Inc., dated: Jan. 20, 2012, 7 pages. |
International Search Report; International Application No. PCT/US2010/042948; Applicant: ReShape Medical, Inc., Mailing Date Apr. 1, 2011, 11 pages. |
International Search Report; International Application No. PCT/US2010/043134; Applicant: ReShape Medical, Inc., Mailing Date Apr. 27, 2011, 12 pages. |
International Search Report; International Application No. PCT/US2010/043136; Applicant: ReShape Medical, Inc., Mailing Date Apr. 12, 2011, 9 pages. |
International Search Report; International Application No. PCT/US2010/050260; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 17, 2011, 9 pages. |
International Search Report; International Application No. PCT/US2011/026233; Applicant: ReShape Medical, Inc., Mailing Date Apr. 26, 2011, 9 pages. |
International Search Report; International Application No. PCT/US2011/031463; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 27, 2011, 10 pages. |
International Search Report; International Application No. PCT/US2003/012782, Applicant: Applied Medical Resources Corporation, dated: Oct. 28, 2003, 7 pages. |
International Search Report; International Application No. PCT/US2006/042336, Applicant: Abdominus, Inc., dated: Mar. 14, 2007, 9 pages. |
International Search Report; International Application No. PCT/US2006/042710, Applicant: Abdominus, Inc. et al., dated: Mar. 15, 2007, 9 pages. |
International Search Report; International Application No. PCT/US2006/042711, Applicant: Abdominus, Inc. et al, dated: Mar. 16, 2007, 9 pages. |
International Search Report; International Application No. PCT/US2006/048647, Applicant: Abdominus, Inc. et al., dated: May 22, 2007, 12 pages. |
International Search Report; International Application No. PCT/US2008/058677, Applicant: ReShape Medical et al., dated: Aug. 21, 2008, 12 pages. |
International Search Report; International Application No. PCT/US2008/068058, Applicant: ReShape Medical, Inc. et al, dated: Nov. 19, 2008, 11 pages. |
International Search Report; International Application No. PCT/US2010/029865, Applicant: ReShape Medical, Inc., dated: Jan. 5, 2011, 9 pages. |
International Search Report; International Application No. PCT/US2011/024077; Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 12 pages. |
International Search Report; International Application No. PCT/US2011/024082, Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 10 pages. |
Japanese Office Action; Application No. 2013-142327, mailed May 29, 2014, 4 pages. |
Japanese Office Action; Application No. 2013-532976; mailed Jun. 26, 2015, 10 pages. |
Japanese Office Action; Application No. 2014-52972, mailed Feb. 25, 2015, 7 pages. |
Japanese Office Action; Application No. 2010-501261, mailed Sep. 7, 2012, 10 pages. |
Japanese Office Action; Application No. 2010-515040, mailed Jan. 7, 2013, 17 pages. |
Japanese Office Action; Application No. 2012-503759, mailed Mar. 24, 2014, 5 pages. |
Japanese Office Action; Application No. 2013-43712, mailed Jan. 8, 2015, 8 pages. |
Japanese Office Action; Application No. 2013-43712, mailed Nov. 15, 2013, 5 pages. |
Japanese Office Action; Application No. 2013-043712, mailed Apr. 22, 2013, 5 pages. |
Ostrovsky, ReShape Inflatable Gastric Balloon going on Trial as Weight Loss Option; http://www.medgadget.com/2010/02/ReShape—inflatable—gastric—balloon—system—going—on—trial—as—weight—loss—option.html Feb. 4, 2010, retrieved on Feb. 10, 2013. |
ReShape Inflatable Gastric Balloon Going on Trial as Weight Loss Option, MedGadget: Internet Journal of Emerging Medical Technologies. Feb. 4, 2010, 5 pages. |
Wahlen CH et al. “The BioEnterics Intragastric Balloon: How to use it” Obesity Surgery 2001; 11:524-527. |
Chou, Chyuan et al., “Structural Effects on the Thermal Properties of PDPS/PDMS Copolymers,” Journal of Thermal Analysis, vol. 40, pp. 657-667, 1993. |
European Search Report for European Application No. 11740535.7, Applicant: ReShape Medical, Inc., mailed Mar. 8, 2016, 14 pages. |
Extended European Search Report; Application No. 15198773.2, Application ReShape Medical Corporation, mailed Jul. 15, 2016, 7 pages. |
Number | Date | Country | |
---|---|---|---|
20150366691 A1 | Dec 2015 | US |
Number | Date | Country | |
---|---|---|---|
61302465 | Feb 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13577618 | US | |
Child | 14839865 | US |